Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Recs

0
Player Avatar acts20 (37.40) Submitted: 9/28/2011 12:06:55 PM : Outperform Start Price: $9.34 DNDN Score: +31.34

oversold.....

Featured Broker Partners


Advertisement